Form 4 for OVID Ovid Therapeutics Inc.

Accepted 2021-07-16 00:00:00 ET · period of report 2021-07-14 · accession 0001209191-21-046995 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-07-16	2021-07-14	OVID	Rakhit Amit	Pres, CMO	M - OptEx	$1.89	+34.0K	760.8K	+5%	+$64.3K
D	2021-07-16	2021-07-14	OVID	Rakhit Amit	Pres, CMO	S - Sale+OE	$3.71	-34.0K	726.8K	-4%	-$126.2K
D	2021-07-16	2021-07-14	OVID	Rakhit Amit	Pres, CMO	M - OptEx	$0.00	+34.0K	91.0K	+60%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-14	M	A	34,017	$1.89	760,840	D	—	—
2	Common	Common Stock	2021-07-14	S	D	34,017	$3.71	726,823	D	—	—	(F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4
3	Derivative	Stock Option (Right to Buy)	2021-07-14	M	A	34,017	$0.00	90,983	D	$1.89 · — to 2029-02-23	34,017 Common Stock	(F2) 25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.